Rationale for combination of paclitaxel and CDK4/6 inhibitor in ovarian cancer therapy — non-mitotic mechanisms of paclitaxel

Abstract

Taxanes and CDK4/6 inhibitors (CDK4/6i) are two families of successful anti-mitotic drugs used in the treatment of solid tumors. Paclitaxel, representing taxane compounds, has been used either alone or in combination with other agents (commonly carboplatin/cisplatin) in the treatment of many solid tumors including ovarian, breast, lung, prostate cancers, and Kaposi’s sarcoma. Paclitaxel has been routinely prescribed in cancer treatment since the 1990s, and its prominent role is unlikely to be replaced in the foreseeable future. Paclitaxel and other taxanes work by binding to and stabilizing microtubules, causing mitotic arrest, aberrant mitosis, and cell death. CDK4/6i (palbociclib, ribociclib, abemaciclib) are relatively new cell cycle inhibitors that have been found to be effective in breast cancer treatment, and are currently being developed in other solid tumors. CDK4/6i blocks cell cycle progression at the G1 phase, resulting in cell death by mechanisms not yet fully elucidated. At first glance, paclitaxel and CDK4/6i are unlikely synergistic agents as both are cell cycle inhibitors that work at different phases of the cell cycle, and few clinical trials have yet considered adding CDK4/6i to existing paclitaxel chemotherapy. However, recent findings suggest the importance of a non-mitotic mechanism of paclitaxel in cancer cell death and pre-clinical data support rationale for a strategic paclitaxel and CDK4/6i combination. In mouse tumor model studies, drug sequencing resulted in differential efficacy, indicating complex biological interactions of the two drugs. This article reviews the rationales of combining paclitaxel with CDK4/6i as a potential therapeutic option in recurrent ovarian cancer.

Contribution of immune cells to cancer-related neuropathic pain: An updated review

“…As one of the most effective chemotherapeutic drugs, paclitaxel is popularly applied for the treatment of solid tumors for example breast cancer, ovarian cancer, and non-small cell lung carcinoma. 54,55,56 Of note, dorsal root ganglion (DRG) infiltration by macrophages contributes to paclitaxel-induced peripheral neuropathy through activating Toll-like receptor 4 (TLR4) and upregulating monocyte chemotactic protein 1 (MCP-1) expression, which for the first time stresses a mechanistic link that TLR4 activation followed by MCP-1 elevation by DRG neurons leads to macrophage infiltration to the DRG during the development of behavioral signs of CIPN. 57 Moreover, Old et al have reported vincristine sulfate (VCR) treatment can improve the adhesion property of endothelial cells, leading to the infiltration of circulating CX3CR1 + monocytes into the sciatic nerve, which has been observed for a murine model of vincristine-induced neuropathic pain.…”

Indian Medicinal Plants for the Management of Endometriosis: A Comprehensive Review on their phytopharmacology

“…It activates signaling pathways that promote apoptotic cell death, leading to the elimination of abnormal cells. This apoptotic effect is thought to contribute to the reduction of endometriotic lesions (Li et al, 2022;Okimura et al, 2018;Smith et al, 2022).…”

Inhibiting MEK1 R189 citrullination enhances the chemosensitivity of docetaxel to multiple tumour cells

“…However, the use of a single chemotherapy drug does not achieve the desired effect [4,5], and long-term use of chemotherapy drugs is also prone to drug resistance [6,7]. Therefore, for the treatment of patients with advanced tumours, a combination of multiple drugs is often applied [8][9][10]. Additionally, the combined therapy strategy not only helps increase the efficacy of chemotherapeutics, but also decreases the dosage of the drugs, as prolonged and high-dose chemotherapy is easily associated with safety issues among clinical trial patients including asthenia, cutaneous reactions, hematological issues and neurosensory reactions [11,12].…”